Case reports of long-term treatment with the oncolytic ECHO-7 virus Rigvir® of rare cancer patients shows surprisingly positive results

The surprisingly positive treatment outcomes using Rigvir® virotherapy for late-stage cancer patients were recently published in the APMIS journal (Acta Pathologica, Microbilogica Et Immunologica Scandinavia). Patients with Stage IV M1c melanoma, Stage IIIA small cell lung cancer and Stage IV histiocytic sarcoma began virotherapy with Rigvir® within a few months of being diagnosed and are continuing to use this treatment. Patients have significantly exceeded the projected life expectancy typically associated with such diagnoses. After beginning the therapy their condition stabilized and their quality of life improved significantly.

The cancer patients described were diagnosed 3.5, 7 and 6.6 years ago. Their conditions have improved and have been stable for over 1.5, 6.5 and 4 years, respectively. They received long-term treatment with Rigvir® oncolytic virotherapy within 1 to 2 months of being diagnosed. These observations suggest that oncolytic virotherapy using Rigvir® can be used successfully in the long-term treatment of patients with Stage IV M1c melanoma, Stage IIIA small cell lung cancer and Stage IV histiocytic sarcoma.


In clinical practice RIGVIR® is also used for other types of cancer, based on the individual recommendations of physicians.

  • melanoma

  • stomach cancer

  • colorectal cancer

  • pancreatic cancer

  • renal cancer

  • uterine cancer

  • bladder cancer

  • lung cancer

  • prostate cancer

  • sarcoma of several types